Format

Send to

Choose Destination
Curr Opin Immunol. 2002 Oct;14(5):652-9.

Immunotherapy of insulin-dependent diabetes mellitus.

Author information

1
UCSF Diabetes Center, Department of Medicine, University of California, San Francisco, CA 94143, USA.

Abstract

Type 1 diabetes mellitus is caused by the T cell mediated autoimmune destruction of insulin-producing beta cells of the islets of Langerhans within the pancreas. Current immunotherapy strategies are aimed at directly inactivating the autoreactive T cells and/or inducing T cells with regulatory capabilities. At the preclinical level, several strategies that employ TCR antagonists -- including monoclonal antibodies, autoantigen-specific peptides and soluble TCR ligands -- are showing promise and being developed for clinical application. Several of these approaches employing monoclonal antibodies against the TCR-CD3 complex or soluble peptide antigens are producing favorable results in the clinic.

PMID:
12183168
DOI:
10.1016/s0952-7915(02)00375-8
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center